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Purpose: To determine the short-term comfort after a single dose of travoprost BAK-free 
compared to latanoprost in primary open-angle glaucoma or ocular hypertensive patients.
Design: Prospective, double-masked, randomized comparison of two separate active agents 
dosed once in opposite eyes.
Methods: At Visit 1, qualiﬁ  ed patients began a glaucoma medicine-free period for three days. At 
Visit 2, patients were randomly assigned to travoprost BAK-free or latanoprost in opposite eyes. 
Following dosing in each eye, patients completed a visual analog scale (VAS score, 0–100 mm) 
at speciﬁ  ed time intervals and a comfort survey.
Results: In 54 completed subjects, no difference existed ﬁ  ve seconds after dosing, in comfort 
on the VAS between latanoprost (7.1 ± 16.2 mm) and travoprost BAK-free (7.8 ± 16.1 mm, 
P = 0.53). Also no differences existed between treatments following dosing for discomfort at 
individual timepoints past ﬁ  ve seconds, peak discomfort or the time required to return to base-
line comfort (P  0.05). In addition, the comfort survey demonstrated no difference between 
products for burning, stinging, foreign body sensation, overall comfort and general acceptance 
between the products, both for absolute levels and changes from baseline (P  0.05).
Conclusion: Following a single instillation, both latanoprost and travoprost BAK-free exhibit 
similar comfort scores.
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Introduction
Glaucoma patients are typically treated medically to lower the intraocular pressure 
to prevent glaucomatous progression.1 Unfortunately, patients may have irritating 
concomitant anterior segment diseases such as lid lag, blepharitis or dry eye, in which 
the use of a glaucoma preparation, which usually includes both a preservative and an 
active ingredient, might further exacerbate their symptoms.2,3
Several years ago, Allergan made available brimonidine purite (Alphagan P™, 
Allergan, Inc., Irvine, CA), a chronically dosed benzalkonium chloride (BAK)-free 
alpha-agonist, which eliminated the BAK preservative. Although the medicine appears 
equal in efﬁ  cacy to BAK-preserved brimonidine, little evidence exists that it improves 
comfort.4
More recently, Alcon released travoprost BAK-free (Travatan Z™, Alcon Laborato-
ries, Inc., Fort Worth, TX) which is a chronically dosed BAK-free prostaglandin. This 
formulation is preserved with Sofzia™, which provides an antimicrobial effect through 
a proprietary formulation of several buffering agents.5 Regulatory trials have indicated 
equivalent efﬁ  cacy between travoprost and the preservative-free formulation.5Clinical Ophthalmology 2009:3 190
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Unfortunately, little information yet is available evaluating 
comfort with travoprost BAK-free. Data might be especially 
important compared to latanoprost (Xalatan®, Pﬁ  zer, New York, 
NY) which is the leading selling glaucoma agent, but also has 
manifested few comfort problems.6,7 The primary objective of 
this study was to determine the short-term comfort after a single 
dose of travoprost BAK-free compared to latanoprost in patients 
with primary open-angle glaucoma or ocular hypertension.
Materials and methods
Patients
The study design was a prospective, double-masked, random-
ized comparison of an active agent in one eye and the active 
control in the opposite eye (intra-individual control).
We included patients with a clinical diagnosis of ocular 
hypertension or primary open-angle, pigment dispersion or 
exfoliation glaucoma with an intraocular pressure considered 
to be safe, in both eyes, for a 3–5 day washout from current 
medical therapy. Patients must have demonstrated best cor-
rected Snellen visual acuity of 20/200 or better in each eye 
and their intraocular pressure must have been 22 mmHg in 
both eyes while treated with any topical ocular prostaglandin 
or 30 mmHg on no medications.
We excluded patients who had a presence of other 
primary or secondary glaucoma not listed in the inclusion 
criterion; any abnormality preventing reliable applanation 
tonometry; any known opacity or patient uncooperativeness 
that restricted adequate examination of the ocular fundus or 
anterior chamber in either study eye; or a concurrent infec-
tious/noninfectious conjunctivitis, keratitis or uveitis in either 
eye. Blepharitis, nonclinically signiﬁ  cant, or prostaglandin-
induced conjunctival injection was allowed.
We also excluded patients who had undergone intra-
ocular conventional surgery or laser surgery less than 
three months prior to Visit 1; were at risk of visual ﬁ  eld or 
visual acuity worsening as a consequence of participation 
in the trial; had progressive retinal or optic nerve disease 
from any cause; demonstrated any clinically signiﬁ  cant, 
serious, or severe medical or psychiatric condition; had 
any condition which would interfere with participation 
in the study or which would present a special risk to the 
patient; demonstrated known allergy, sensitivity or poor 
tolerance to any components of the preparations used in 
this trial; had a history of, or were at risk for uveitis or 
cystoid macular edema; had a history of ocular herpes 
simplex; or required use of ocular or oral corticosteroids, 
contact lenses or topical ocular cyclosporine currently or 
within the past 30 days.
Procedures
At Visit 1, patients signed an Institutional Review Board 
informed consent form. Patients then underwent an exami-
nation which included: Goldmann applanation tonometry, 
Snellen visual acuity, and slit lamp biomicroscopy, and 
completed the Ocular Surface Disease Index (OSDI) survey.7 
Patients whom the investigator believed could safely stop 
their current glaucoma medications for 3–5 days, and met 
the inclusion/exclusion criteria, were enrolled into the study. 
Patients were instructed to stop their glaucoma medication(s) 
at the end of Visit 1.
Visit 2 (Day 1) occurred 3–5 days or longer after Visit 1. 
The washout period was not designed to obtain an accurate 
baseline for the intraocular pressure but to allow for normal 
turnover of epithelial cells on the anterior surface of the eye 
to assess comfort.7 Patients again underwent visual acuity 
testing and slit lamp biomicroscopy. Patients also completed 
a baseline visual analog scale, which evaluated global 
comfort, and a comfort survey which assessed speciﬁ  c ante-
rior segment side effects. Afterwards, patients were randomly 
assigned to which eye would receive medicine ﬁ  rst and which 
eye was dosed with travoprost BAK-free (Travatan Z™, 
Alcon Laboratories) or latanoprost (Xalatan™, Pﬁ  zer).
Patients were randomized to the masked study medicine 
and were dosed by an unmasked dosing coordinator. Imme-
diately following dosing of one drop of the study medicine 
in the ﬁ  rst eye, patients completed the visual analog scale 
(VAS) at every ﬁ  ve seconds up to one minute and then at 
2, 5, 10, 15, 20, and 30 minutes, or until comfort returned to 
baseline (+2 mm or less). Following the visual analog scale 
patients completed the comfort survey for only a single 
instance. When all procedures were completed for the ﬁ  rst 
eye, the second eye was dosed with the other medication 
by the unmasked dosing coordinator, and all post-dosing 
procedures performed for the ﬁ  rst eye were measured again 
for the second eye.
After all comfort evaluations were ﬁ  nished, Goldmann 
applanation tonometry was measured in both eyes. Also, 
a global product preference was collected. This test provided 
the patient a choice of which product (identiﬁ  ed only as 
product #1 or #2) was most comfortable, or alternatively, 
that there was no preference between the two. In addition, 
any adverse events were recorded.
Statistics
The data was analyzed by PRN Pharmaceutical Research 
Network, LLC. All data analyses were two-sided and had 
an α-level of 0.05.9,10Clinical Ophthalmology 2009:3 191
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The primary safety variable was the VAS measured 
immediately after dosing. The visual analog scale used 
for this study (Product Comfort Preference Scale©, Alcon 
Laboratories) is scored from 0–100 with ‘0’ representing 
no pain and ‘100’ being the greatest possible pain. The test 
consists of a simple horizontal which represents their per-
ceived pain from ‘0’ (perfect comfort) to ‘100’ (the worst 
pain imaginable). The patient marks the point along the line 
that represents their perceived pain.
The study was sized based on a paired t-test model. Travo-
prost BAK-free was hypothesized to have a comfort level just 
above placebo and similar to brinzolamide (approximately 
7 mm).10 In contrast, latanoprost was hypothesized to have an 
approximate comfort level twice as good as dorzolamide.11 
These hypotheses supposed that approximately a 5 mm dif-
ference existed between groups. Consequently, if 51 patients 
completed the study, assuming a standard deviation of 10 mm 
for travoprost BAK-free and 22 mm for latanoprost, then 
the study had an 80% power to exclude a 5 mm difference 
between groups.12
The VAS immediately after dosing, the VAS at each time-
point following dosing apart from the initial measurement, and 
the comfort survey for each question (The Nine Point Comfort 
Survey©, Alcon Laboratories) were analyzed by a one-way 
ANOVA test within a Matched Pairs platform to determine 
a signiﬁ  cant difference between eyes.13 In addition, the peak 
measure, and the length of time until return to baseline on the 
VAS, also were analyzed by a one-way ANOVA test within 
a Matched Pairs platform. Apart from the primary endpoint, 
a Bonferroni correction was used to adjust the p-values for the 
three scales because of multiple measures.14 ANOVA evalua-
tions were performed on all measured parameters both for the 
absolute levels as well as the changes from baseline.14
Slit lamp biomicroscopy and concomitant medications 
were described and not evaluated statistically. Visual acuity 
and intraocular pressure were analyzed between eyes by 
a one-way ANOVA test within a Matched Pairs platform. 
Adverse events were analyzed between eyes by a McNemar 
test.14 In contrast, patient global preference was evaluated 
by a chi-square test.14
Results
Patients
Patient characteristics for the 54 completed subjects are 
shown in Table 1. No unusual characteristics of our patient 
population for the United States were obvious. One additional 
subject was terminated from the study between Visits 1 and 
2 because he was lost to follow-up.
Comfort
The primary endpoint showed that there was no signiﬁ  cant 
difference at ﬁ  ve seconds after dosing in mean comfort on the 
visual analogue scale between latanoprost (7.1 ± 16.2 mm) 
and travoprost BAK-free (7.8 ± 16.1 mm, P = 0.53) above 
a common untreated baseline of 7.5 ± 15.9 mm.
Further, the mean peak level of discomfort was 8.4 ± 16.5 mm 
for latanoprost and 10.5 ± 17.0 mm for travoprost BAK-free 
(P = 0.21). The most common time after dosing that the 
Table 1 Patient characteristics
Characteristic N Percentage
A. Gender
Female 37 68.5%
Male 17 31.5%
B. Race
Caucasian 42 77.8%
Black 9 16.7%
Hispanic 2 3.7%
Middle Eastern 1 1.9%
C. Iris color
Hazel 24 44.4%
Brown 20 37.0%
Green 6 11.1%
Blue 4 7.4%
D. Medical history
Cardiovascular arterial hypertension 39 72.2%
Cardiovascular lipid disorders 25 46.3%
Endocrine diabetes 19 35.2%
E. Opthalmic history
Primary open-angle glaucoma 35 64.8%
Ocular hypertension 16 29.6%
Pigmentary glaucoma 3 5.6%
F. Glaucoma medication history
Latanoprost 0.005% 29 35.2%
Travoprost 0.004% 18 33.3%
Bimatoprost 0.03% 6 11.1%
Mean number of glaucoma medications 1.82
Mean time on glaucoma medications 
(in years)
12.56
G. Eyes assigned to each medicine
OD
Test medication
Latanaprost 25 46.3%
Travaprost BAK-free 29 53.7%
OS
Latanaprost 29 53.7%
Travaprost BAK-free 25 46.3%Clinical Ophthalmology 2009:3 192
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peak effect occurred was ﬁ  ve seconds for latanoprost (range 
5–600 seconds) and ﬁ  ve seconds for travoprost BAK-free 
(range 5–120 seconds). The mean time required to return to 
baseline comfort was 16.8 ± 84.1 seconds for latanoprost 
and 6.7 ± 23.7 seconds for travoprost BAK-free (P = 0.41). 
Further, at no time point following dosing was there a signiﬁ  -
cant difference between treatments for the level of comfort 
(P  0.05; Please see Table 2). In addition, no differences 
were observed between products when classiﬁ  ed as to sever-
ity by the baseline OSDI. The actual power to exclude a 5 mm 
difference between groups was 99.9% based on a standard 
deviation of 5 mm, ﬁ  ve seconds after dosing.
In addition, the comfort survey demonstrated no differ-
ence between products for burning, stinging, foreign body 
sensation, overall comfort and general acceptance of the 
product, both of absolute levels and changes from baseline 
(P  0.05; see Table 3).
Following study medicine dosing and all comfort 
measures, the mean intraocular pressure for the travoprost 
BAK-free treated eye was 20.2 ± 5.4 mmHg and for the 
latanoprost-treated eye,19.8 ± 4.7 mmHg (P = 0.22). Mean 
Snellen visual acuity was for the travoprost BAK-free-treated 
eye was 20/25.3±7.0 and for the latanoprost-treated eye 
was 20/25.6 ± 8.0 (P = 0.71). Latanoprost was preferred by 
17 (31%), travoprost BAK-free by 18 (33%), and no prefer-
ence was given by 19 (35%) patients (P = 0.92).
Adverse effects
Only one adverse event was noted in this single dose study. 
Hypertrichosis was noted in both eyes in one patient. This 
event was not believed by the investigator to be related to 
the study medicines. There were no serious adverse events 
during the study.
Discussion
A high percent of glaucoma patients suffer from chronic 
ocular surface diseases.11 Further, antiglaucoma medications 
are often associated with ocular adverse reactions such as dry 
eye, and burning or stinging sensations.15 These undesirable 
effects potentially might lead to treatment discontinuation 
and reduced quality of life.11
BAK is the preservative in the great majority of medicines 
to treat glaucoma.16 Recent research has noted, however, that 
BAK also may be toxic to the anterior segment epithelium 
Table 2 Mean post-dosing readings on the product preference scale
Mean
Time (seconds) N Latanoprost Travoprost BAK-free P-value
55 4 7.1 ± 16.2 7.8 ± 16.1 0.53
10 54 6.8 ± 15.4 7.4 ± 15.8 0.55
15 54 7.0 ± 15.2 7.2 ± 15.3 0.84
20 54 6.8 ± 15.2 7.3 ± 15.2 0.58
25 54 6.8 ± 15.2 7.0 ± 15.2 0.81
30 54 7.0 ± 15.5 6.7 ± 15.0 0.73
35 54 7.0 ± 15.5 6.4 ± 15.0 0.40
40 54 6.8 ± 15.2 6.4 ± 15.0 0.47
45 54 6.8 ± 15.2 6.4 ± 15.0 0.47
50 54 6.8 ± 15.2 6.7 ± 15.1 0.90
55 54 6.8 ± 15.2 6.6 ± 15.1 0.80
60 54 6.8 ± 15.2 6.6 ± 15.1 0.71
120 54 7.2 ± 15.3 7.6 ± 16.4 0.78
300 54 6.9 ± 15.2 7.2 ± 15.9 0.80
600 54 6.9 ± 15.2 6.5 ± 15.4 0.61
900 54 6.8 ± 15.2 5.7 ± 15.1 0.06
1200 54 6.8 ± 15.2 5.7 ± 15.1 0.06
1800 54 6.7 ± 15.2 5.8 ± 15.1 0.11
Peak 54 8.4 ± 16.5 10.5 ± 17.0 0.21
Return to baseline 
(seconds)
54 16.8 ± 84.1 6.7 ± 23.7 0.41Clinical Ophthalmology 2009:3 193
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of the eye.16 Consequently, the development of antiglaucoma 
medicines that are preserved without BAK might help reduce 
anterior segment symptoms in patients.
Travoprost BAK-free was recently released commercially 
as the ﬁ  rst non-BAK-preserved prostaglandin. Baudouin has 
noted in an in-vitro conjunctival cell line that the travoprost 
BAK-free solution did not demonstrate the toxic effects of 
BAK-preserved prostaglandin preparations or BAK alone.17 
Further, Yee and colleagues have shown reduced in-vitro 
corneal cell toxicity with travoprost BAK-free as opposed 
to the commercial latanoprost preparation.18 In addition, 
Kahook and Noecker demonstrated in rabbits less deleteri-
ous effects on the ocular surface with non-BAK-preserved 
medications.19 In patients, the presence of BAK in prosta-
glandin formulations has been associated with more anterior 
segment side effects than those treated with the travoprost 
BAK-free preparation.20
The primary objective of this study was to determine the 
short-term comfort after a single dose of travoprost BAK-free 
compared to latanoprost in patients with primary open-angle 
glaucoma or ocular hypertension.
This study showed that the endpoint, the VAS at ﬁ  ve 
seconds after dosing, showed only very mild discomfort and 
no signiﬁ  cant difference between latanoprost (7.1 ± 16.2 mm) 
and travoprost BAK-free (7.8 ± 16.1 mm).
Further, secondary safety variables showed no differ-
ences between treatments following dosing for discomfort 
at any individual time point, time of peak discomfort, or the 
time required to return to baseline comfort. In addition, the 
comfort survey demonstrated no difference between products 
for burning, stinging, foreign body sensation, overall comfort 
and general acceptance of the product, by both absolute levels 
and changes from baseline.
Since BAK is known to have toxic effects on the ante-
rior surface of the eye, a difference in comfort might have 
been anticipated between a glaucoma medicine containing 
a high percentage of BAK (latanoprost) and one without 
(travoprost BAK-free). The reason for a lack of difference 
in comfort between the study medicines is not known pre-
cisely by our results but may have been derived from the 
following. First, latanoprost is known as a fairly comfortable 
medicine despite its higher concentration of BAK. Accord-
ingly, Stewart and colleagues noted in healthy individuals 
only minimal differences in anterior segment staining with 
latanoprost following three days of dosing to untreated 
baseline.21 A longer-term dosing trial with latanoprost may 
be needed to demonstrate a difference in comfort favoring 
travoprost BAK-free.
Second, as this current study was a single-dose comparison 
in patients who had been washed out of their active medication 
for at least three days, the surface may have recovered from 
any anterior segment toxic effects associated with the prior 
glaucoma medicine. Consequently, a single dose of medication, 
even with BAK present, may not have had a sufﬁ  cient impact 
to differentiate comfort between products on the relatively 
healthy epithelium. In a longer term study chronically dosed 
BAK may demonstrate a greater likelihood to induce inﬂ  am-
mation and subsequent apoptosis, causing clinical symptoms 
and an irritated anterior segment. In such a clinical setting, 
differentiation of comfort between the two study medications, 
one with and one without BAK, may have a greater likelihood 
of success consistent with several past studies.20
This study suggests that following a single drop, both 
latanoprost and travoprost BAK-free exhibit similar levels 
of very transient and mild discomfort.
This study did not evaluate chronic dosing of latanoprost 
versus travoprost BAK-free on comfort. As mentioned above, 
longer-term dosing may have found clinical differences in 
signs or symptoms between a BAK preserved solution and 
one without. In addition, this study did not evaluate quality of 
life and compliance in patients treated with a BAK-preserved 
and -free solutions. Any glaucoma medication that produces 
chronic irritation11 potentially may more likely cause non-
compliance23 and problems with activities of daily living.24 
Table 3 Comfort survey results
Baseline Latanoprost Travoprost BAK-free
Time (seconds) Mean Mean P-value Mean P-value
NPCS burning 7.5 ± 15.9 8.4 ± 16.5 0.37 10.5 ± 17.0 0.06
NPCS stinging 0.2 ± 0.8 0.1 ± 0.7 0.18 0.1 ± 0.7 0.18
NPCS foreign body 0.04 ± 0.3 0.02 ± 0.1 0.32 0.02 ± 0.1 0.32
NPCS general discomfort 0.1 ± 1.0 0.02 ± 0.1 0.40 0.02 ± 0.1 0.40
NPCS overall accept 0.5 ± 1.1 0.2 ± 0.7 0.04 0.3 ± 1.1 0.30
Abbreviation: NPCS, Nine Point Comfort Survey.Clinical Ophthalmology 2009:3 194
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More research is needed generally to fully deﬁ  ne the impact 
of BAK on patients’ lives and to further develop medications 
which can be dosed chronically without a harsh active preser-
vative and maintain sterility.
Disclosure
This study was sponsored by an unrestricted grant from Alcon 
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